These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20795590)

  • 1. Treatment settings and metabolic monitoring for people experiencing first-episode psychosis.
    Batscha C; Schneiderhan ME; Kataria Y; Rosen C; Marvin RW
    J Psychosoc Nurs Ment Health Serv; 2010 Sep; 48(9):44-9. PubMed ID: 20795590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents.
    Schneiderhan ME; Batscha CL; Rosen C
    Pharmacotherapy; 2009 Aug; 29(8):975-87. PubMed ID: 19637951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia.
    Brunero S; Lamont S; Fairbrother G
    Arch Psychiatr Nurs; 2009 Jun; 23(3):261-8. PubMed ID: 19446781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications.
    Hasnain M; Vieweg WV; Fredrickson SK; Beatty-Brooks M; Fernandez A; Pandurangi AK
    Prim Care Diabetes; 2009 Feb; 3(1):5-15. PubMed ID: 19083283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme.
    Barnes TR; Paton C; Hancock E; Cavanagh MR; Taylor D; Lelliott P;
    Acta Psychiatr Scand; 2008 Jul; 118(1):26-33. PubMed ID: 18582345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic abnormalities in an early psychosis service: a retrospective, naturalistic cross-sectional study.
    Curtis J; Henry C; Watkins A; Newall H; Samaras K; Ward PB
    Early Interv Psychiatry; 2011 May; 5(2):108-14. PubMed ID: 21470374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted intervention to improve monitoring of antipsychotic-induced weight gain and metabolic disturbance in first episode psychosis.
    Thompson A; Hetrick SE; Alvarez-Jiménez M; Parker AG; Willet M; Hughes F; Gariup M; Gomez DL; McGorry PD
    Aust N Z J Psychiatry; 2011 Sep; 45(9):740-8. PubMed ID: 21827345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Easy and low-cost identification of metabolic syndrome in patients treated with second-generation antipsychotics: artificial neural network and logistic regression models.
    Lin CC; Bai YM; Chen JY; Hwang TJ; Chen TT; Chiu HW; Li YC
    J Clin Psychiatry; 2010 Mar; 71(3):225-34. PubMed ID: 19814949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic screening in children receiving antipsychotic drug treatment.
    Morrato EH; Nicol GE; Maahs D; Druss BG; Hartung DM; Valuck RJ; Campagna E; Newcomer JW
    Arch Pediatr Adolesc Med; 2010 Apr; 164(4):344-51. PubMed ID: 20368487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Who should swing the stethoscope? An audit of baseline physical examination and blood monitoring on new patients accepted by an early intervention in psychosis team.
    Crabb J; McAllister M; Blair A
    Early Interv Psychiatry; 2009 Nov; 3(4):312-6. PubMed ID: 22642736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring.
    De Hert M; van Eyck D; De Nayer A
    Int Clin Psychopharmacol; 2006 Mar; 21 Suppl 2():S11-5. PubMed ID: 16601508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The incidence of metabolic risk factors in an inpatient psychiatric setting.
    Coakley C; Bolton P; Flaherty L; Kopeski LM; Slifka K; Sutherland MA
    J Psychosoc Nurs Ment Health Serv; 2012 Mar; 50(3):24-30. PubMed ID: 22329619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness.
    Holt RI; Abdelrahman T; Hirsch M; Dhesi Z; George T; Blincoe T; Peveler RC
    J Psychopharmacol; 2010 Jun; 24(6):867-73. PubMed ID: 19304868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a metabolic screening bundle on rates of screening for metabolic syndrome in a psychiatry resident outpatient clinic.
    Wiechers IR; Viron M; Stoklosa J; Freudenreich O; Henderson DC; Weiss A
    Acad Psychiatry; 2012 Mar; 36(2):118-21. PubMed ID: 22532201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic medications and diabetes mellitus.
    Weinberg AD; Weinberg JD
    Director; 2003; 11(3):111-3. PubMed ID: 13678022
    [No Abstract]   [Full Text] [Related]  

  • 18. Nursing care of clients treated with atypical antipsychotics who have a risk of developing metabolic instability and/or type 2 diabetes.
    Edward KL; Rasmussen B; Munro I
    Arch Psychiatr Nurs; 2010 Feb; 24(1):46-53. PubMed ID: 20117688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.
    Morrato EH; Cuffel B; Newcomer JW; Lombardo I; Kamat S; Barron J
    J Clin Psychopharmacol; 2009 Feb; 29(1):26-32. PubMed ID: 19142103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the initial treatment phase in first-episode psychosis.
    Power P; Elkins K; Adlard S; Curry C; McGorry P; Harrigan S
    Br J Psychiatry Suppl; 1998; 172(33):71-6. PubMed ID: 9764130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.